Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

65.62USD
24 Mar 2017
Change (% chg)

$-0.03 (-0.05%)
Prev Close
$65.65
Open
$65.51
Day's High
$66.11
Day's Low
$65.32
Volume
4,056,311
Avg. Vol
7,113,701
52-wk High
$68.12
52-wk Low
$55.06

Select another date:

Mon, Mar 20 2017

BRIEF-Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln

* CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing

BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir

* Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c

BRIEF-Abbvie CEO Richard Gonzalez's total 2016 compensation was $21 mln vs. $20.8 mln in 2015

* CEO Richard Gonzalez's total 2016 compensation was $21 million versus $20.8 million in 2015 - sec filing

BRIEF-Abbvie's CEO total 2016 compensation was $21 mln - SEC filing

* CFO William Chase's 2016 total compensation was $8.8 million versus $7.6 million in 2015

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

BRIEF-Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax

* Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

BRIEF-Abbvie announces $5 bln increase to stock repurchase program

* Abbvie announces $5 billion increase to stock repurchase program Source text for Eikon: Further company coverage:

BRIEF-Abbvie sets quarterly cash dividend of $0.64 per share

* Sets quarterly cash dividend of $0.64 per share Source text for Eikon: Further company coverage:

Jury clears Abbott and AbbVie in Depakote birth defect trial

A federal jury in Ohio on Thursday found that drug manufacturers Abbott Laboratories Inc and AbbVie Inc were not responsible for birth defects in a boy whose mother took their antiepileptic drug Depakote while pregnant.

BRIEF-Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir

* Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of chronic hepatitis c in all major genotypes (GT1-6) Source text for Eikon: Further company coverage:

Select another date:

More From Around the Web